Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.

Journal of Crohn's & colitis - 5 Feb 2026

Hodges Phoebe, Roberts Christopher, Parkes Miles, Kennedy Nicholas A, Goodhand James, Ahmad Tariq

Abstract excerpt

BACKGROUND AND AIMS: Immunogenicity and the development of an undetectable drug level is a modifiable cause of anti-tumor necrosis factor (anti-TNF) treatment failure. We modeled the clinical utility of pre-treatment HLA-DQA1*05:01 and HLA-DQA1*05:05 allele subtype testing to guide immunomodulator use in patients with Crohn's disease treated with an anti-TNF. METHODS: The Personalised Anti-TNF Therapy in Crohn's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TNF gene

Share to Genotype

Share to HLA-DQ alpha-Chains

Share to Infliximab

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 41423739
DOI: 10.1093/ecco-jcc/jjaf233

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.PMID 41423739Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity Read ↗

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity Read ↗

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.Semantic proximity Read ↗

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studySemantic proximity Read ↗

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.Semantic proximity Read ↗

Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.